Properties
What is it?
International Nonproprietary Name - budesonide, formoterol Clinical-pharmacological group: Glucocorticosteroid preparations for inhalation use. Composition and dosage form: Each delivered dose (mouthpiece dose) contains as active substances: Budesonide ... 80 mcg Formoterol fumarate dihydrate .... 4.5 mcg Budesonide .... 160 mcg Formoterol fumarate dihydrate ..... 4.5 mcg Budesonide ..... 320 mcg Formoterol fumarate dihydrate ... 4.5 mcg. Excipient: Lactose monohydrate. Budesonide. Budesonide is a glucocorticosteroid that, after inhalation, exhibits a rapid (within a few hours) and dose-dependent anti-inflammatory effect on the respiratory tract. It reduces the severity of symptoms and the frequency of asthma exacerbations. Compared to the use of systemic glucocorticosteroids, the use of inhaled budesonide results in a lower incidence of side effects. It reduces swelling of the bronchial mucosa, mucus secretion, moisture, and hyperreactivity of the airways. The exact mechanism of the anti-inflammatory action of glucocorticosteroids is unknown. Formoterol. Formoterol is a selective agonist of beta 2-adrenergic receptors. After its inhalation, relaxation of the smooth muscles of the bronchi is observed in patients with reversible airway obstruction. The dose-dependent bronchodilator effect appears within 1-3 minutes after inhalation and lasts for 12 hours after a single dose. Indications: - Bronchial asthma, for maintenance therapy and relief of exacerbations (when inhaled corticosteroids and short-acting beta 2-adrenoceptor agonists provide insufficient control, or when inhaled corticosteroids and long-acting beta 2-adrenoceptor agonists provide adequate control). - Chronic obstructive pulmonary disease (symptomatic therapy in patients with severe COPD (forced expiratory volume in 1 second < 50% of the predicted value) and recurrent exacerbations in the history, despite long-acting bronchodilator therapy, the disease remains significantly symptomatic). Chronic obstructive pulmonary disease Adults: 160/4.5 mcg/dose, 2 inhalations daily. Instructions for correct use of Turbuhaler: Mechanism of action of Turbuhaler: The drug reaches the respiratory tract when inhaled from its mouthpiece. Patients should be warned: - To carefully read the instructions for using Turbuhaler. - To inhale strongly and deeply from the mouthpiece to ensure optimal drug delivery to the lungs. - Never to exhale into the mouthpiece. - To rinse the mouth with water after each maintenance dose inhalation to reduce the risk of developing oral candidiasis. Also, when inhaling to relieve symptoms, if oral candidiasis develops, the mouth should be rinsed with water. After using Turbuhaler, the patient may not feel the drug or its taste, which is due to the small volume of the delivered substance.